Working... Menu

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02141451
Recruitment Status : Active, not recruiting
First Posted : May 19, 2014
Last Update Posted : January 28, 2019
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : January 23, 2019
  Estimated Study Completion Date : May 2020